Observational studyMedicine2017
Cancer incidence and mortality in Hebei province, 2013.
Observational study in Medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The association between ambient air pollution and the risk of incident nasopharyngeal carcinoma in Hangzhou, China.Scientific reports · 2024Article
- Cellular zinc metabolism and zinc signaling: from biological functions to diseases and therapeutic targets.Signal transduction and targeted therapy · 2024Review
- Lung cancer risk and exposure to air pollution: a multicenter North China case-control study involving 14604 subjects.BMC pulmonary medicine · 2023Article
- Mortality and Years of Life Lost Due to Brain and Other Central Nervous System Cancer in Wuhan, China, from 2010 to 2019.International journal of environmental research and public health · 2023Article
- Epidemiological characteristics and risk factors of lung adenocarcinoma: A retrospective observational study from North China.Frontiers in oncology · 2022Article
- Breast Cancer Epidemiology and Survival Analysis of Shenyang in Northeast China: A Population-Based Study from 2008 to 2017.The breast journal · 2022Article
- Epidemiology and prognosis in young lung cancer patients aged under 45 years old in northern China.Scientific reports · 2021Article
- Comprehensive analysis of the expression of SLC30A family genes and prognosis in human gastric cancer.Scientific reports · 2020Article
- Small cell lung cancer (SCLC) incidence and trends vary by gender, geography, age, and subcategory based on population and hospital cancer registries in Hebei, China (2008-2017).Thoracic cancer · 2020Article
- Fine particulate matter associated mortality burden of lung cancer in Hebei Province, China.Thoracic cancer · 2018Article
- Trends and Patterns of Cancer Mortality in North China (Hebei Province), 1973-2013.Scientific reports · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To estimate the numbers of new cancer cases and deaths in Hebei province in 2013 and to investigate the real cancer burden in Hebei province to develop strategies for cancer prevention and control.Data on new cancer cases and deaths in 2013 were collected from 31 population-based cancer registries of Hebei province. All data were checked and evaluated based on data quality criteria from the "Chinese Guideline for Cancer Registration" and "Cancer Incidence in Five Continents Volume IX" by the International Agency for Research on Cancer/International Association of Cancer Registration (IARC/IACR). Qualified data from 21 registries were used for analysis after evaluation. Data analysis was stratified by areas (urban/rural), gender, age group, and cancer type. New cancer cases and deaths in Hebei province were estimated using age-specific rates and the corresponding provincial population. The 10 most common cancers in different groups and the cumulative rates were calculated. The Chinese population census in 2000 and the population of Segi were used for age-standardized incidence/mortality rates.The covered populations included 11, 185,626 people (5,709,393 in males and 5,476,233 in females) from 21 qualified cancer registries, accounting for 15.25% of Hebei provincial population. The major indicators of quality control, that is, the percentage of cases morphologically verified (MV%), percentage of cancer cases identified with a death certificate only (DCO%), and the mortality to incidence rate ratio (M/I), were 75.56%, 3.23%, and 0.65, respectively. In 2013, it was estimated that there were approximately 164,100 newly diagnosed cancer cases and 105,200 cancer deaths in Hebei province. The incidence rate of cancer was 225.36/100,000 (248.03/100,000 in males, 201.73/100,000 in females), and the age-standardized incidence rates by Chinese standard population (ASIRC) and the world standard population (ASIRW) were 182.81/100,000 and 181.36/100,000, respectively. The cancer incidence and ASIRC were 225.49/100,000 and 173.84/100,000 in urban areas and 225.27/100,000 and 189.31/100,000 in rural areas, respectively. The cancer mortality rate was 145.46/100,000 (177.85/100,000 in males and 111.70/100,000 in females). Age-standardized mortality rates by Chinese standard population (ASMRC) and world standard population (ASMRW) were 119.09/100,000 and 118.73/100,000, respectively. The cancer mortality rate in rural areas (152.64/100,000) was higher than that in urban areas (135.71/100,000). The most common cancers were lung cancer, stomach cancer, esophageal cancer, liver cancer, breast cancer, and colorectal cancer. Lung cancer, stomach cancer, liver cancer, esophageal cancer, and colorectal cancer were the major causes of cancer death in Hebei province.The coverage of cancer registration population has rapidly increased and may reveal the cancer burden in Hebei province more comprehensively. The cancer burden in Hebei province is heavy, and prevention and control measures should be enhanced.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.